Asparlas

Chemical Namecalaspargase pegol-mknl
Dosage FormInjection (intravenous; 3,750 units/5 mL)
Drug ClassEnzymes
SystemBlood
CompanyServier Pharmaceuticals LLC.
Approval Year2018

Indication

  • Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.
Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Asparlas (Calaspargase Pegol-mknl) Prescribing Information 2018Servier Pharmaceuticals LLC., Boston, MA
Document TitleYearSource
Pediatric acute lymphoblastic leukemia, version 2.2020. 2020NCCN Clinical Practice Guidelines in Oncology